These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 7255533)

  • 1. [Characterization of the crystallization behavior of poorly soluble drugs in suspensions].
    Rupprecht H; Ziller KH
    Pharmazie; 1981 Apr; 36(4):298. PubMed ID: 7255533
    [No Abstract]   [Full Text] [Related]  

  • 2. Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications.
    Deng Z; Xu S; Li S
    Int J Pharm; 2008 Mar; 351(1-2):236-43. PubMed ID: 18093763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels.
    Zahedi P; Lee PI
    Eur J Pharm Biopharm; 2007 Mar; 65(3):320-8. PubMed ID: 17182231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of calcined Mg-Al-hydrotalcite to enhance the stability of celecoxib in the amorphous form.
    Ambrogi V; Perioli L; Marmottini F; Rossi C
    Eur J Pharm Biopharm; 2007 May; 66(2):253-9. PubMed ID: 17123798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A technical feasibility study of surfactant-free drug suspensions using octenyl succinate-modified starches.
    Kuentz M; Egloff P; Röthlisberger D
    Eur J Pharm Biopharm; 2006 May; 63(1):37-43. PubMed ID: 16356701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supercritical carbon dioxide processing of active pharmaceutical ingredients for polymorphic control and for complex formation.
    Moribe K; Tozuka Y; Yamamoto K
    Adv Drug Deliv Rev; 2008 Feb; 60(3):328-38. PubMed ID: 18006109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents.
    Kawakami K; Oda N; Miyoshi K; Funaki T; Ida Y
    Eur J Pharm Sci; 2006 May; 28(1-2):7-14. PubMed ID: 16406526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of the effect of some drugs on the dissolution rate of nitrofurantoin.
    Naggar VF; Shams-Eldeen MA
    Pharmazie; 1980; 35(9):550-2. PubMed ID: 7433507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of Silymarin nanocrystals lyophilized power applying nanosuspension technology].
    Zhao X; Wang G; Zhang B; Li H; Nie Q; Zang C; Zhao X
    Zhongguo Zhong Yao Za Zhi; 2009 Jun; 34(12):1503-8. PubMed ID: 19777833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanosuspensions in drug delivery.
    Rabinow BE
    Nat Rev Drug Discov; 2004 Sep; 3(9):785-96. PubMed ID: 15340388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel cubic phase of medium chain lipid origin for the delivery of poorly water soluble drugs.
    Kossena GA; Charman WN; Boyd BJ; Porter CJ
    J Control Release; 2004 Sep; 99(2):217-29. PubMed ID: 15380632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-solubilization of poorly soluble drugs by micellization and complexation.
    Rao VM; Nerurkar M; Pinnamaneni S; Rinaldi F; Raghavan K
    Int J Pharm; 2006 Aug; 319(1-2):98-106. PubMed ID: 16765542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base.
    Hecq J; Deleers M; Fanara D; Vranckx H; Boulanger P; Le Lamer S; Amighi K
    Eur J Pharm Biopharm; 2006 Nov; 64(3):360-8. PubMed ID: 16846725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel pH-sensitive supramolecular assemblies for oral delivery of poorly water soluble drugs: preparation and characterization.
    Sant VP; Smith D; Leroux JC
    J Control Release; 2004 Jun; 97(2):301-12. PubMed ID: 15196757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of a novel phospholipid-based depot injectable technology for poorly water-soluble drugs.
    Tiemessen H; van Hoogevest P; Leigh ML
    Eur J Pharm Biopharm; 2004 Nov; 58(3):587-93. PubMed ID: 15451533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs.
    Kocbek P; Baumgartner S; Kristl J
    Int J Pharm; 2006 Apr; 312(1-2):179-86. PubMed ID: 16469459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expulsion of lipophilic drugs from the cores of solid lipid microspheres in diluted suspensions and in concentrates.
    Pietkiewicz J; Sznitowska M; Placzek M
    Int J Pharm; 2006 Mar; 310(1-2):64-71. PubMed ID: 16413712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system.
    Pouton CW
    Eur J Pharm Sci; 2006 Nov; 29(3-4):278-87. PubMed ID: 16815001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal growth in aqueous suspensions.
    Varney G
    J Pharm Pharmacol; 1967 Dec; 19():Suppl:19S-23S. PubMed ID: 4383851
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.